"Ethyl eicosapentaenoic acid" from_date:2012

Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. Atherosclerotic cardiovascular disease (ASCVD) and its atherothrombotic complications impose a substantial disease burden in Europe, representing a cost of €210 billion per year for the European Union. Hypertriglyceridemia, a major risk factor

Cost-effectiveness of ethyl-eicosapentaenoic acid in the treatment of bipolar disorder Cost-effectiveness of ethyl-eicosapentaenoic acid in the treatment of bipolar disorder ..

Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study). Icosapent ethyl is pure prescription eicosapentaenoic acid approved at 4 g/day as an adjunct to diet to reduce triglycerides (TG) in adults with TG ≥500 mg/dl. Elevated

Solid Dose Form of Metformin with Ethyl Eicosapentaenoic Acid Does Not Improve Metformin Plasma Availability. The purpose of the study was to investigate effects of ethyl eicosapentaenoic acid on pharmacokinetics of metformin. Pharmacokinetic profiles of metformin and ethyl eicosapentaenoic acid when delivered separately or together in solid dose form were investigated and compared to determine whether the solid dose resulted in an altered metforminpharmacokinetics when given with or without food. A single-center, open-label, repeated dose study investigated the pharmacokinetic (PK) profile of metformin when administered in solid dose form with ethyl eicosapentaenoic acid compared to co-administration with icosapent ethyl, an ester of eicosapentaenoic acid and ethyl alcohol used to treat

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Remnant-like particle cholesterol (RLP-C) is atherogenic and may increase atherosclerotic cardiovascular disease risk. Icosapent ethyl is a high-purity prescription eicosapentaenoic acid ethyl ester (approved as an adjunct to diet to reduce triglyceride [TG

Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials). There are limited data on the efficacy and safety of triglyceride (TG)-lowering agents in women. We conducted subgroup analyses of the effects of icosapent ethyl (a high-purity prescription form of the ethyl ester of the omega-3 fatty acid

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies.

Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome. The aim of this analysis was to examine the effects of icosapent ethyl (eicosapentaenoic acid ethyl ester, IPE) on high-sensitivity C-reactive protein (hsCRP) and lipid parameters in patients with metabolic syndrome, with and without

Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial. It has been suggested that treatment with ethyl-eicosapentaenoic acid (EPA) may improve motor function in patients with Huntington's disease (HD) with cytosine-adenine-guanine repeat numbers of <45. This multicenter, randomized, double-blind, placebo-controlled 6-month trial compared the effects

Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Pharmacokinetic Parameters of Rosiglitazone in Healthy Subjects Icosapent ethyl is a high-purity form of eicosapentaenoic acid ethyl ester approved to reduce triglyceride levels in adults with triglycerides ≥500 mg/dL. Candidates for triglyceride-lowering therapy include patients with diabetes mellitus who may be receiving

A PET Study With [11C]PBR-28 and an Experimental Medication, Ethyl Eicosapentaenoic Acid This pilot study will ask whether omega three fatty acids have an antidepressant effect in bipolar depression by decreasing brain inflammation. undefined

pharmacological practices in Huntington's disease. Revue Neurologique (Paris) 2016;172(8–9):423–432. doi: 10.1016/j.neurol.2016.07.012. [PubMed] [CrossRef] [Google Scholar]19. Ferreira JJ, Rosser A, Craufurd D, Squitieri F, Mallard N, Landwehrmeyer B. Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial. Movement Disorders. 2015;30(10):1426–1429. doi: 10.1002/mds

, though their ototoxicity outweighed their benefits. Moreover, small molecules with structural similarity to cholesterol may also perturb cholesterol-cholesterol interactions and prevent from expansion of 2D crystalline domains to large 3D CCs. The results from ethyl eicosapentaenoic acid and ursodeoxycholic acid were encouraging and worth further consideration. In this review, the significance of CCs

acids to treat schizophrenia; 7 of these were included in a Cochrane systematic review. The quality of the reported data was often poor, and the studies were small and short term. Efficacy Efficacy The Cochrane review reported on 3 RCTs that measured overall mental health. Two RCTs (Fenton et al. 2001 and Berger et al. 2007) showed that omega-3 fatty acids (ethyl-eicosapentaenoic acid [E-EPA] 2 or 3 g Rating Scale; CGI, Clinical Global Impressions Scale; CGI-S, Clinical Global Impressions-Severity of Illness scale; DHA, docosahexaenoic acid; E-EPA, ethyl-eicosapentaenoic acid; EPA, eicosapentaenoic acid; GAF, Global Assessment of Functioning scale; n, number of participants; PANSS, Positive and Negative Syndrome Scale; SANS, Scale for the Assessment of Negative Symptoms; SOFAS, Social

to residual atherosclerotic cardiovascular disease (ASCVD) risk, particularly among patients with type 2 diabetes mellitus, metabolic syndrome, and obesity whose distinctive lipid phenotype cannot be optimally treated with LDL-C reduction therapy alone; (ii) describe the findings and clinical implications of the landmark REDUCE-IT trial in which ethyl eicosapentaenoic acid significantly improved ASCVD

-eicosapentaenoic acid"[Title/Abstract]))) AND ((("Autism Spectrum Disorder"[MeSH]) OR "Child Development Disorders, Pervasive"[MeSH]) OR (((((("autism"[Title/Abstract]) OR ("autism spectrum disorder"[Title/Abstract])) OR ("ASD"[Title/Abstract])) OR ("Asperger"[Title/Abstract])) OR ("Pervasive development disorder"[Title/Abstract])) OR ("PPD"[Title/Abstract])))) AND ((("Systematic Review" [Publication Type .PubMed :(((((("Fatty Acids, Omega-3"[MeSH]) OR "Eicosapentaenoic Acid"[MeSH]) OR "Docosahexaenoic Acids"[MeSH]) OR "Linoleic Acid"[MeSH]) OR ((((((("omega 3"[Title/Abstract]) OR ("omega-3 fatty acid"[Title/Abstract])) OR ("Eicosapentaenoic Acid"[Title/Abstract])) OR ("Docosahexaenoic Acids"[Title/Abstract])) OR ("Linoleic Acid"[Title/Abstract])) OR ("lipoic acid"[Title/Abstract])) OR ("ethyl

-on therapy in reducing psychopathology in populations of chronic patients with schizophrenia, only a few concern first-episode schizophrenia. The majority of these studies used a 12-week intervention based on ethyl-eicosapentaenoic acid (ethyl-EPA), however, with conflicting results. An intervention based on docosahexaenoic acid plus EPA has not been used in first-episode schizophrenia studies so far